Background: Dyslipidemia increases the frequency and severity of micro and macrovascular complications of type 1 diabetes (T1D). The present study aims to determine the prevalence of dyslipidemia and its association with clinical and laboratory findings in diabetic children and adolescents. Methods: The study included 202 children and adolescents with T1D. Demographic data and laboratory findings were obtained from patients files. Results: Dyslipidemia prevalence was found to be 26.2%. Hypercholesterolemia (15.8%) and hyperglyceridemia (12.9%) were most common findings. Age, body mass index (BMI), hemoglobin A 1c (A 1C ) and poor metabolic control were significantly higher in cases with dyslipidemia. Smoking rate was 14.1% in the pubertal group. Poor metabolic control and dyslipidemia was found higher among smokers (p < 0.05).Conclusions: Blood lipid levels should be monitored regularly and nutrition education should be repeated periodically to prevent and control dyslipidemia in patients with T1D. Smoking-related risks should be a part of patient education in the pubertal period.

Introduction: Hashimoto thyroiditis (HT) is a common chronic autoimmune thyroid disease. Many studies on autoimmune diseases have investigated human cathelicidin from the anti-microbial peptide family. This article aims to determine the level of cathelicidin in Hashimoto's thyroiditis and evaluate its relationship with thyroid functions. Material and Method: Eighty-eight subjects were included in the study. Gender, age, and BMI were similar between 48 HT patients and 40 healthy controls. Cathelicidin levels were studied in serum samples with an ELISA kit. Results: There were euthyroid and subclinical hypothyroid HTs in the study. There was a significant difference between the controls and patients in terms of TSH (p<0.001), fT4 (p=0.001), anti-TPO (p=0.001), and anti-Tg (p=0.001). Median cathelicidin level was significantly higher in the HT group (853.53 pg/ml) than in the control group (577.08 pg/ml) (p<0.001). Cathelicidin levels were similar (p=0.555) in HT with euthyroid and subclinical hypothyroidism. There were no correlations between cathelicidin level and age, year of disease, BMI, TSH, fT4, fT3, anti-TG, and anti-TPO. Diagnosis of HT was approximately 5.6 times higher in patients with high cathelicidin values (p<0.001). The possible effect of cathelicidin on the development of HT was evaluated by univariate binary logistic regression analysis, and the diagnostic threshold for cathelicidin was found to be 714 pg/ml (sensitivity 71%, specificity 70%). Conclusion: Our study is the first to examine the relationship between HT and serum cathelicidin. High cathelicidin was associated with HT independent of thyroid hormone levels, a possible role in the pathogenesis of HT.